Shimada Furitsu, Endo Hiroyoshi, Takamori Ayako, Matsunaga Takuya, Fujimoto Shun, Shirai Shimpei, Kakiuchi Toshihiko, Akutagawa Takashi, Sakata Yasuhisa, Node Koichi, Yamanouchi Kohei, Nakamura Shotaro, Fujimoto Kazuma, Esaki Motohiro
Division of Gastroenterology Saiseikai Karatsu Hospital Saga Japan.
Department of Internal Medicine, Faculty of Medicine Saga University Saga Japan.
JGH Open. 2021 Nov 10;5(11):1284-1288. doi: 10.1002/jgh3.12666. eCollection 2021 Nov.
The aim of the present study was to examine the lifestyle- and comorbidity-related determinant factors of the prescription of proton pump inhibitors (PPIs) for patients in whom has been eradicated, and to evaluate the relationship between PPI prescription and the severity of endoscopic esophagitis.
This retrospective study included patients who underwent eradication from May 2012 to September 2016 at Saiseikai Karatsu Hospital. All patients received upper gastrointestinal endoscopy before eradication. Patients with open peptic ulcers and/or malignant diseases were excluded, and a final total of 389 patients were evaluated. Medical records were reviewed to determine the prescription of PPIs after eradication, lifestyle-related factors, and comorbidities. Lifestyle-related factors were confirmed by a questionnaire.
PPIs were administered to 124 of 389 patients (31.9%). The only lifestyle-related risk factor for the prescription of PPIs after eradication was older age ( < 0.01). Hypertension increased the prescription of PPIs ( = 0.034). The prescription of PPIs was not influenced by the presence of grade A esophagitis, whereas the PPI prescription rate was significantly increased in patients with grades B/C/D endoscopic esophagitis ( < 0.01). The grade of chronic gastritis before eradication had no effect on the prescription of PPIs.
The lifestyle- and comorbidity-related risk factors for the prescription of PPIs after eradication were older age and hypertension, while mild endoscopic esophagitis had no influence on PPI prescription.
本研究旨在探讨幽门螺杆菌已根除患者中与生活方式及合并症相关的质子泵抑制剂（PPI）处方决定因素，并评估PPI处方与内镜下食管炎严重程度之间的关系。
这项回顾性研究纳入了2012年5月至2016年9月在佐世保市西桂医院接受幽门螺杆菌根除治疗的患者。所有患者在幽门螺杆菌根除治疗前均接受了上消化道内镜检查。排除患有开放性消化性溃疡和/或恶性疾病的患者，最终共评估了389例患者。查阅病历以确定幽门螺杆菌根除治疗后PPI的处方情况、与生活方式相关的因素以及合并症。通过问卷调查确认与生活方式相关的因素。
389例患者中有124例（31.9%）接受了PPI治疗。幽门螺杆菌根除治疗后，PPI处方的唯一与生活方式相关的危险因素是年龄较大（P＜0.01）。高血压会增加PPI的处方率（P = 0.034）。A级食管炎的存在对PPI的处方没有影响，而内镜下B/C/D级食管炎患者的PPI处方率显著增加（P＜0.01）。幽门螺杆菌根除治疗前慢性胃炎的分级对PPI的处方没有影响。
幽门螺杆菌根除治疗后，与生活方式及合并症相关的PPI处方危险因素是年龄较大和高血压，而轻度内镜下食管炎对PPI处方没有影响。
